Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 04 04:00PM ET
1.55
Dollar change
+0.13
Percentage change
9.15
%
Index- P/E- EPS (ttm)-10.69 Insider Own5.79% Shs Outstand2.37M Perf Week1.31%
Market Cap3.67M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float2.23M Perf Month-9.36%
Income-23.35M PEG- EPS next Q- Inst Own7.27% Short Float11.32% Perf Quarter-13.41%
Sales0.00M P/S- EPS this Y- Inst Trans-92.68% Short Ratio5.41 Perf Half Y-26.19%
Book/sh-0.02 P/B- EPS next Y- ROA-68.51% Short Interest0.25M Perf Year-90.77%
Cash/sh5.51 P/C0.28 EPS next 5Y- ROE-297.63% 52W Range1.16 - 18.75 Perf YTD-80.03%
Dividend Est.- P/FCF- EPS past 5Y67.29% ROI-6108.28% 52W High-91.73% Beta2.19
Dividend TTM- Quick Ratio2.48 Sales past 5Y-20.00% Gross Margin- 52W Low33.61% ATR (14)0.18
Dividend Ex-Date- Current Ratio2.48 EPS Y/Y TTM-3.61% Oper. Margin0.00% RSI (14)50.16 Volatility16.14% 11.78%
Employees6 Debt/Eq0.08 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price32.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-34.61% Payout- Rel Volume0.25 Prev Close1.42
Sales Surprise-14.63% EPS Surprise-79.41% Sales Q/Q- Earnings- Avg Volume46.68K Price1.55
SMA206.96% SMA50-8.00% SMA200-46.77% Trades Volume11,735 Change9.15%
Oct-02-24 09:10AM
Aug-21-24 09:00AM
Jul-24-24 09:05AM
Jul-22-24 09:00AM
Jul-15-24 07:52AM
09:00AM Loading…
Jun-17-24 09:00AM
May-21-24 09:00AM
09:00AM
May-17-24 03:52PM
Apr-09-24 08:21AM
Mar-05-24 09:15AM
Feb-13-24 11:45AM
Dec-29-23 12:45PM
Dec-06-23 09:15AM
Oct-19-23 09:00AM
07:30AM Loading…
Oct-04-23 07:30AM
Aug-14-23 08:30AM
Aug-02-23 08:30AM
Jul-31-23 09:00AM
Apr-12-23 08:30AM
Mar-20-23 08:55AM
Mar-08-23 08:30AM
Mar-02-23 08:30AM
Feb-28-23 08:30AM
Feb-21-23 08:45AM
Dec-06-22 09:40AM
Nov-17-22 08:00AM
Nov-14-22 08:00AM
Sep-20-22 08:00AM
Aug-30-22 08:30AM
09:45AM Loading…
Aug-03-22 09:45AM
Jul-29-22 09:19AM
Jul-26-22 07:30AM
Jul-12-22 09:30AM
Jun-21-22 10:30AM
Apr-05-22 09:15AM
Mar-24-22 09:26AM
Feb-23-22 09:15AM
Feb-20-22 08:37AM
Feb-08-22 09:15AM
Feb-07-22 08:38PM
Jan-05-22 09:15AM
Dec-29-21 09:15AM
Dec-16-21 10:50AM
Dec-01-21 10:05AM
Nov-23-21 09:25AM
Nov-18-21 09:15AM
Nov-16-21 09:25AM
Nov-15-21 09:45AM
Oct-26-21 10:30AM
Oct-19-21 10:30AM
Oct-05-21 10:00AM
Sep-22-21 11:00AM
Sep-13-21 10:00AM
Sep-09-21 10:15AM
Aug-24-21 10:17AM
Aug-23-21 08:47AM
Aug-10-21 02:30PM
10:30AM
Aug-05-21 10:30AM
Jul-27-21 09:15AM
Jul-07-21 09:00AM
Jun-07-21 10:02AM
May-17-21 09:00AM
May-12-21 09:00AM
May-10-21 09:00AM
Apr-28-21 10:13AM
Apr-22-21 09:20AM
TNF Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company that engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in Baltimore, MD.